Aerska closes €32 million round to push longevity science
Irish biotech startup Aerska has raised €32 million in fresh funding to accelerate therapies designed, in the company’s own words, to “enable our loved ones to live longer.” The financing marks one of the more significant early-stage bets in Europe’s fast-emerging longevity biotech sector.
While the startup is keeping some scientific details under wraps, Aerska is understood to be developing targeted interventions that address the biological mechanisms of ageing, with the goal of extending the number of years people spend in good health rather than merely prolonging life.
Targeting the biology of ageing
The new capital will be used to expand laboratory capabilities, grow the scientific team and advance preclinical programmes focused on age-related diseases. By concentrating on the root causes of cellular damage, Aerska aims to develop therapies that could delay or prevent conditions such as cardiovascular disease, neurodegeneration and metabolic disorders.
Investors are increasingly drawn to longevity research as breakthroughs in biotechnology, genomics and AI-driven drug discovery shorten development cycles and reduce costs. The €32 million round signals rising confidence that European startups can compete with US and Asian players in this strategically important field.
Strengthening Europe’s longevity ecosystem
The funding will also allow Aerska to deepen collaborations with universities, clinical centres and regulatory experts across Europe. Building this network is seen as critical to moving from early-stage discovery towards human trials and, eventually, approved therapies.
For policymakers and healthcare systems facing rapidly ageing populations, the promise of clinically validated longevity therapeutics is substantial: fewer years spent in chronic illness, lower long-term healthcare costs and a more active older population. By securing significant backing at this stage, Aerska positions itself as a notable European contender in the global race to extend healthy human lifespans.